Bio-Rad Laboratories, Inc.NYSE
Advanced Chart
  • Jun. 9, 2015, 8:55 PM
    • GE's $12B deal to sell its U.S. private-equity lending business to Canada Pension Plan Investment Board is just the beginning of its plan to shed ~$200B of GE Capital assets - and a whole lot of cash to spend on takeovers.
    • Although GE may not make a move right away as it tries to complete the $14B purchase of most of Alstom’s energy business, Bloomberg figures it could amass a $40B war chest for takeovers.
    • Among speculated targets: Pentair (NYSE:PNR), a provider of water pumps and filtration systems; Flowserve (NYSE:FLS), a maker of industrial pumps and valves; electrical components manufacturer Hubbell (HUB.A, HUB.B); life sciences equipment maker Bio-Rad Laboratories (NYSE:BIO); and some of the assets Halliburton (NYSE:HAL) and Baker Hughes (NYSE:BHI) will divest as part of their merger.
    • Whatever the target, acquisitions likely will be part of GE’s transformation after asset sales and returning capital to shareholders.
    | Jun. 9, 2015, 8:55 PM | 26 Comments
  • Apr. 9, 2012, 2:16 PM

    Bio-Rad Laboratories (BIO +1.1%) could be a tasty purchase due its low valuation and prudent management, according to analysts. Chatter on the street sees the life-science equipment maker making a nice "bolt-on" acquisition for either Thermo Fisher (TMO +3.1%) or Life Technologies (LIFE -1.6%).

    | Apr. 9, 2012, 2:16 PM | 1 Comment
  • Jul. 5, 2011, 10:16 AM

    TPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers.

    | Jul. 5, 2011, 10:16 AM | 1 Comment